Guidance & Visibilty

[madrose1]

Large Cap Gainers

VRTX (83.21 +57.39%): Announced that treatment with VX-661 and Ivacaftor in a Phase 2 study resulted in statistically significant improvements in lung function in people with cystic fibrosis who have two copies of the F508del mutation

CMG (359.68 +9.54%): Beat quarterly EPS by $0.31 ($2.45 including $0.10 tax benefit vs $2.14 estimate), revs rose 13.5% yoy to $726.8 mln vs $274.74 mln estimate; reported Q1 comparable restaurant sales rose 1%; sees FY13 comparable restaurant sales growth in low single digits

COF (56.03 +6.13%): Reporeted Q1 GAAP EPS of $1.79 per share, may not compare to $1.60 estimate; revs rose 12.5% yoy to $5.55 bln vs $5.57 bln estimate

Large Cap Losers IBM (192.49 -7.08%): Missed quarterly EPS by $0.06 ($3.00 vs $3.06 estimate), revs fell 5.1% yoy to $23.41 bln vs $24.66 bln estimate; reaffirmed FY13 EPS of at least $16.70 vs $16.78 estimate

WIT (8.06 -4.89%): Reported Q4 earnings of INR 7.02 vs INR 6.98 estimate, revs rose 11.7% yoy to INR 110.26 bln vs INR 110.39 bln estimate
ISRG (472.47 -4.24%): Beat quarterly EPS by $0.54 ($4.56 vs $4.02 estimate), revs rose 23.5% yoy to $611.4 mln vs $582.92 mln estimate; da Vinci surgical procedures grew ~18%; sees FY13 revs at higher end of previously provided +16-19% range, sees FY13 procedures growth at low end of previously provided +20-23% range

Mid Cap Gainers CE (47.07 +11.46%): Reported Q1 adjusted EPS of $1.14, may not compare to $0.79 estimate; revenues fell 1.7% yoy to $1.61 bln vs $1.61 bln estimate; GAAP EPS was $0.88 vs $0.78 estimate

MMS (78.93 +8.23%): Upgraded to Outperform from Market Perform at Raymond James

MAN (54.56 +5.92%): Beat quarterly EPS by $0.18 ($0.63 ex items vs $0.45 estimate), revs fell 6.4% yoy to $4.77 bln vs $4.76 bln estimate; sees Q2 EPS of $0.84-0.92 vs $0.76 estimate
Mid Cap Losers PAY (18.95 -4.58%): Downgraded to Neutral from Buy at Compass Point, target lowered to $20 from $25

HMSY (24.47 -2.63%): Downgraded to Equal Weight from Overweight at First Analysis
TCB (14.07 -1.47%): Missed quarterly EPS by $0.03 ($0.16 vs $0.19 estimate); net interest margin was 4.27% compared with 4.14% in prior year